AstraZeneca should still know by year-end whether its experimental vaccine protects people against coronavirus, as long as it is cleared to resume trials soon, its chief executive said on Thursday amid doubts over its rollout.
FILE PHOTO: A test tube labelled with the Vaccine is seen in front of AstraZeneca logo in this illustration taken, September 9, 2020. REUTERS/Dado Ruvic/Illustration
The World Health Organization has flagged the AstraZeneca vaccine, which is being developed with the University of Oxford, as the most promising for coronavirus. “It’s very common, actually, and many experts will tell you this,” Soriot said, adding: “The difference with other vaccine trials is, the whole world is not watching them, of course. They stop, they study, and they restart.”
With up to 60,000 people set to participate in the study program, AstraZeneca’s CEO said the volume was typical of vaccine trials and large enough to spot rare side effects. The U.S.-based Mayo Clinic concludes that the association so far is not strong enough to warrant limiting any vaccine.
Deutschland Neuesten Nachrichten, Deutschland Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
AstraZeneca Pauses Covid-19 Vaccine Trial After Illness in a U.K. SubjectAstraZeneca said it paused clinical trials of an experimental Covid-19 vaccine after a participant in a U.K. study had an unexplained illness.
Weiterlesen »
AstraZeneca pauses Covid-19 vaccine trial – latest updatesA look at latest developments in global Covid-19 crisis👇: 💉 AstraZeneca suspends vaccine trial after one illness 🇬🇧 UK plans hiring spree to harness big data in virus recovery 🇧🇷 Brazil eyes vaccine rollout in January For more:
Weiterlesen »
Trump's warp speed COVID vaccine plan hits snag as AstraZeneca pauses trialPhase 3 trials for AstraZeneca's COVID-19 vaccine candidate were paused Tuesday due to a 'potentially unexplained illness in one of the trials.'
Weiterlesen »
AstraZeneca puts leading COVID-19 vaccine trial on hold over safety concernAstraZeneca Plc on Tuesday said it has paused global trials, including large late-stage trials, of its experimental coronavirus vaccine because of an unexplained illness in a study participant.
Weiterlesen »
AstraZeneca Pauses COVID-19 Vaccine Trial Due To Volunteer's IllnessNPR's Noel King talks to Paul Offit of the Vaccine Education Center at Children's Hospital of Philadelphia, about the coronavirus vaccine trial developed by AstraZeneca and the University of Oxford.
Weiterlesen »
Why AstraZeneca pausing its COVID-19 vaccine trial may be good newsAstraZeneca has temporarily put the brakes on its late-stage, global COVID-19 vaccine trial after a participant came down with what experts call an 'adverse event.'
Weiterlesen »